Imara M&A

Selectivity over EGFR ELVN-002 was >100x More Selective for HER2 YVMA Relative to EGFR Than Dual EGFR/HER2 Competitors 1000 100 10 1 0.1 Mobocertinib Poziotinib >100x Pyrotinib Investigational dual inhibitors ORR = Overall response rate. NSCLC = Non-small cell lung cancer. TKI = Tyrosine kinase inhibitor. BDTX-189 ELVN-002 } Our selective product candidate A431/ Beas2b HER2 YVMA H2073/Beas2b HER2 YVMA Current investigational dual EGFR/HER2 TKIs are roughly equipotent against EGFR and HER2 YVMA Lack of Differentiation Across Next Generation TKIs HN HN. HN 'N HN. Neratinib HN CN Pyrotinib HN CN BDTX-189 Poor efficacy & tolerability in HER2 mutant setting Phase 1b/2 30% ORR in HER2 mutant NSCLC, poor tolerability Poor efficacy & tolerability in HER2 mutant setting 39

View entire presentation